Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
smallpox alphavaccine
- Development stage
- Preclinical
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The smallpox alphavaccine is an investigational biodefense vaccine developed by AlphaVax using its proprietary Viral Replicon Particle (VRP) technology. The vaccine platform is derived from an attenuated Venezuelan Equine Encephalitis (VEE) virus, where the viral structural genes are replaced with sequences encoding specific smallpox (Variola virus) antigens, such as L1R, A33R, B5R, and A27L. These replication-deficient VRPs function as a delivery vehicle for replicon RNA; once they infect host cells, the RNA self-amplifies and produces high levels of the target smallpox antigens without generating new infectious virus particles. This mechanism is designed to induce a potent and balanced immune response, including both neutralizing antibodies and cellular immunity, providing a safer alternative to traditional live-vaccinia virus vaccines for protection against smallpox.
- Other names
- AlphaVax smallpox vaccineVRP smallpox vaccineRNA particle smallpox vaccinesmallpox (biodefence) alphavaccine
02
Targets
A27 (Orthopoxvirus A27 protein)B5R (B5 orthopoxvirus envelope protein)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)OPXV MV/EEV antigens (Orthopoxvirus mature virion and extracellular enveloped virion surface antigens)
Beyond the preview
Go deeper on smallpox alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on smallpox alphavaccine.